发布求助
搜索
全部 求助中 待确认 已完结
其它数据库
求助中 Outcomes and Treatments of Patients With Non–Small Cell Lung Cancer Who Received Pembrolizumab
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
其它数据库
已完结 Overall Survival With First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer A Randomized Clinical Trial
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
下载文件
其它数据库
已完结 Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer.
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
下载文件
其它数据库
求助中 Radiotherapy-free pembrolizumab combined with chemotherapy for locally advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50% or higher (Evolution trial): a multicentre, single-arm, phase 2 study
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
其它数据库
已完结 Cost-Effectiveness of Adjuvant Immunotherapy in Cancer Treatments: A Systematic Review.
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
下载文件
Elsevier
求助中 Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
Elsevier
已完结 Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
下载文件
其它数据库
已完结 Systemic therapy sequence and outcomes in unresectable hepatocellular carcinoma: results from the multicenter Tokai Post ICI Sequential Therapy Registry cohort.
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
下载文件
其它数据库
已完结 Chapter One - Antibody drug conjugates beyond cytotoxic payloads
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
下载文件
其它数据库
已完结 Emerging EGFR-Targeted Therapy in Head and Neck Cancer
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
下载文件
其它数据库
求助中 Chinese expert consensus on radiotherapy combined with immunotherapy for unresectable lung cancer (2026 Edition)
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
Elsevier
已完结 Validation of the lung immune prognostic index in extensive-stage small cell lung cancer: Post hoc analysis of the caspian and IMpower133 phase 3 trials
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
下载文件
其它数据库
求助中 PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression: A Systematic Review and Meta-Analysis.
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
Elsevier
求助中 Intratumoral heterogeneity and immunotherapy resistance: clinical implications
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
其它数据库
求助中 The next generation of antibody–drug conjugates
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
Elsevier
已完结 Advances And Challenges in Immunosuppressive Antibody Drug Conjugates
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
下载文件
其它数据库
已完结 Assessment of endpoint definitions in curative-intent trials for mucosal head and neck squamous cell carcinomas: Head and Neck Cancer International Group consensus recommendations
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
下载文件
其它数据库
已完结 Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendations
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
下载文件
其它数据库
已完结 Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trial
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
下载文件
其它数据库
已完结 Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
下载文件